Living our culture, delivering for the Patients !!

Cardiovascular Diseases ( CVD), Diabetes and Obesity are the risks associated due to poor metabolism and commonly referred as “LIFESTYLE DISEASES”. Bioaltus Labs envisage the need to address the concerns of the patients with the metabolic syndrome and emphasis is led on the Research, Innovation and Development of the newer therapies. The Research & Development team has put lot of efforts in developing the new drugs in the category of the SGLT2 inhibitors ( Sodium-Glucose Cotransporter-2 Inhibitors) and DPP-4 Inhibitors ( Dipeptidyl Peptidase-4 Inhibitors). The research team Is also working on the developing and the commercializing the newer and novel therapy for the glucose reducing medication called as “ GLIMINS”, It has a unique mechanism of action that targets the three main pathophysiologic components of type 2 diabetes: impaired glucose uptake by muscle tissue, excess hepatic gluconeogenesis and increase β-cell apoptosis